Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.315 USD | -1.48% | +12.78% | -51.31% |
Financials (USD)
Sales 2024 * | 282M | Sales 2025 * | 386M | Capitalization | 456M |
---|---|---|---|---|---|
Net income 2024 * | -185M | Net income 2025 * | -89M | EV / Sales 2024 * | 2.72 x |
Net Debt 2024 * | 309M | Net Debt 2025 * | 230M | EV / Sales 2025 * | 1.78 x |
P/E ratio 2024 * |
-2.12
x | P/E ratio 2025 * |
-4.15
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.43% |
Latest transcript on Revance Therapeutics, Inc.
1 day | +6.83% | ||
1 week | +21.33% | ||
Current month | +21.33% | ||
1 month | -0.68% | ||
3 months | -18.59% | ||
6 months | -49.01% | ||
Current year | -50.17% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 0 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 4.278 | -2.34% | 250 359 |
24-05-07 | 4.38 | +6.83% | 1,348,284 |
24-05-06 | 4.1 | +3.80% | 1,144,396 |
24-05-03 | 3.95 | +4.77% | 1,370,606 |
24-05-02 | 3.77 | -0.66% | 1,256,213 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-50.17% | 456M | |
-2.35% | 89.33B | |
+3.29% | 41.19B | |
-15.40% | 31.87B | |
+53.11% | 24.52B | |
-14.35% | 15.68B | |
-39.65% | 12.23B | |
-6.52% | 12.34B | |
-13.41% | 12.21B | |
+5.77% | 8.83B |
- Stock Market
- Equities
- RVNC Stock